Payment overview · 2025
General Payments
$1,505.80
64 reported records · 12 companies
Healthcare provider profile · identity verified
Juan A Cortes, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1508957804
Verified facts
What the public records show
CMS Open Payments records show Juan A Cortes, D.O. received $1,505.80 in general payments during 2025 across 64 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $415.35 | 27.6% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $364.22 | 24.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $356.60 | 23.7% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.18 | 4.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.09 | 3.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.11 | 3.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.72 | 3.2% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $34.43 | 2.3% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $34.37 | 2.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $31.29 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.94 | 1.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $21.50 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,505.80 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $364.22 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $273.05 | 13 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $240.13 | 11 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $230.15 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.30 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.18 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.40 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.09 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.11 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $31.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 237 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 290 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 416 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
416 | 82 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
109 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
237 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
290 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1422 | 302 |
| Montelukast Sodium | Montelukast Sodium | 1370 | 300 |
| Amlodipine Besylate | Amlodipine Besylate | 1186 | 241 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 1141 | 244 |
| Losartan Potassium | Losartan Potassium | 910 | 182 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 906 | 212 |
| Omeprazole | Omeprazole | 803 | 161 |
| Metformin Hcl | Metformin Hcl | 798 | 151 |
| Famotidine | Famotidine | 778 | 159 |
| Metoprolol Succinate | Metoprolol Succinate | 743 | 144 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 624 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 591 | 124 |
| Gabapentin | Gabapentin | 587 | 113 |
| Diclofenac Sodium | Diclofenac Sodium | 580 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 106 |
| Meloxicam | Meloxicam | 501 | 114 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 433 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 427 | 89 |
| Linzess | Linaclotide | 416 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 377 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 374 | 74 |
| Simvastatin | Simvastatin | 370 | 75 |
| Januvia | Sitagliptin Phosphate | 363 | 59 |
| Enalapril Maleate | Enalapril Maleate | 325 | 68 |
| Ibuprofen | Ibuprofen | 320 | 87 |
| Zolpidem Tartrate | Zolpidem Tartrate | 319 | 56 |
| Jardiance | Empagliflozin | 290 | 56 |
| Alprazolam | Alprazolam | 276 | 62 |
| Levofloxacin | Levofloxacin | 271 | 197 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 254 | 59 |
| Celecoxib | Celecoxib | 240 | 56 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 239 | 72 |
| Farxiga | Dapagliflozin Propanediol | 237 | 40 |
| Prednisone | Prednisone | 233 | 148 |
| Escitalopram Oxalate | Escitalopram Oxalate | 211 | 42 |
| Lisinopril | Lisinopril | 210 | 41 |
| Alendronate Sodium | Alendronate Sodium | 197 | 38 |
| Meclizine Hcl | Meclizine Hcl | 194 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 37 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 184 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 179 | 46 |
| Furosemide | Furosemide | 173 | 30 |
| Ozempic | Semaglutide | 161 | 29 |
| Valsartan | Valsartan | 159 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 150 | 25 |
| Carvedilol | Carvedilol | 142 | 25 |
| Eliquis | Apixaban | 142 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 18 |
| Vascepa | Icosapent Ethyl | 132 | 26 |
| Cilostazol | Cilostazol | 129 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 127 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 125 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 118 | 21 |
| Ammonium Lactate | Ammonium Lactate | 116 | 23 |
| Single Use Swab | Alcohol Antiseptic Pads | 114 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 30 |
| Trulicity | Dulaglutide | 112 | 17 |
| Azelastine Hcl | Azelastine Hcl | 110 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 31 |
| Synthroid | Levothyroxine Sodium | 109 | 23 |
| Xarelto | Rivaroxaban | 108 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 17 |
| Pregabalin | Pregabalin | 107 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 103 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 89 |
| Glipizide Er | Glipizide | 97 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 96 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 28 |
| Finasteride | Finasteride | 87 | 17 |
| Azithromycin | Azithromycin | 85 | 70 |
| Memantine Hcl | Memantine Hcl | 84 | 13 |
| Tramadol Hcl | Tramadol Hcl | 84 | 14 |
| Valacyclovir | Valacyclovir Hcl | 84 | 20 |
| Donepezil Hcl | Donepezil Hcl | 80 | 14 |
| Atenolol | Atenolol | 76 | 17 |
| Mirtazapine | Mirtazapine | 74 | 13 |
| Nifedipine Er | Nifedipine | 73 | 14 |
| Novolog Flexpen | Insulin Aspart | 73 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 71 | 26 |
| Repaglinide | Repaglinide | 70 | 14 |
| Metformin Hcl Er | Metformin Hcl | 69 | 14 |
| Tradjenta | Linagliptin | 69 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 66 | suppressed |
| Glimepiride | Glimepiride | 65 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 65 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 63 | 25 |
| Terazosin Hcl | Terazosin Hcl | 63 | suppressed |
| Folic Acid | Folic Acid | 61 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 60 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Ezetimibe | Ezetimibe | 55 | 14 |
| Lidocaine | Lidocaine | 55 | suppressed |
| Glipizide | Glipizide | 53 | 13 |
| Potassium Chloride | Potassium Chloride | 53 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 50 | 11 |
| Proctozone-Hc | Hydrocortisone | 48 | 16 |
| Procto-Med Hc | Hydrocortisone | 46 | 15 |
| Mupirocin | Mupirocin | 43 | 28 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 42 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | suppressed |
| Ketoconazole | Ketoconazole | 41 | 12 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 40 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 31 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 35 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Terconazole | Terconazole | 34 | 18 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 18 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 22 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | 13 |
| Mupirocin | Mupirocin Calcium | 15 | suppressed |
| Prolia | Denosumab | 15 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,505.80 · 64 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, APTIMA, COMIRNATY, CREON, Cologuard Collection Kit, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LINZESS, LOREEV XR, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error